1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

[Updated] - Potential addiction treatment lands $3.9 million research grant

By Balzafire, Oct 5, 2010 | Updated: Oct 5, 2010 | | |
  1. Balzafire
    The National Institute on Drug Abuse (NIDA) has awarded LSU Health Sciences Center – Shreveport (LSUHSC-S) a $3.9 million dollar research grant over four years to fund the next stages of development of a novel treatment for cocaine dependence.

    Nicholas Goeders, Ph.D., Professor and Head Department of Pharmacology, Toxicology & Neuroscience developed the potential treatment based on his lab research.

    His $3.9 million grant from the NIDA of the National Institutes of Health is the largest individual research project grant, known as a RO-1 grant, ever received by LSUHSC-S, according to available LSUHSC-S records.

    October 4, 2010


  1. Balzafire
    Re: Potential addiction treatment lands $3.9 million research grant

    $3.9M grant for work on anti-addiction drug
    SHREVEPORT, La. (AP) - The National Institute on Drug Abuse gives a Louisiana researcher $3.9 million to keep working on a potential drug to treat cocaine addiction, and to begin tests on people.

    That word is from Embera NeuroTherapeutics, Inc., which has LSU's license to develop the drug worked up by Nicholas Goeders of the LSU Health Sciences Center-Shreveport.

    Goeders is both head of the medical school's pharmacology department and Embera's chief scientific officer.

    The drug combines two already on the market - the tranquilizer oxazepam (ox-AZ-uh-pam) and metyrapone (muh-TIE-ruh-pone), which reduces a body's ability to pump out the stress hormone cortisol (KOHR-tuh-sol).

    Goeders says preliminary tests indicate the drug might also help people stop smoking.

    The vast majority of tested drugs never make it to market.

    Associated Press
    October 5, 2010
To make a comment simply sign up and become a member!